Total Valuation
Jazz Pharmaceuticals has a market cap or net worth of €13.77B. The enterprise value is €18.93K.
Market Cap€13.77B
Enterprise Value€18.93K
Share Statistics
Jazz Pharmaceuticals has 62,817,627 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding62,817,627
Owned by Insiders3.53%
Owned by Institutions3.04%
Financial Efficiency
Jazz Pharmaceuticals’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is 1.22%.
Return on Equity (ROE)-0.08
Return on Assets (ROA)-0.03
Return on Invested Capital (ROIC)1.22%
Return on Capital Employed (ROCE)0.02
Revenue Per Employee1.48M
Profits Per Employee-123.23K
Employee Count2,890
Asset Turnover0.37
Inventory Turnover1.21
Valuation Ratios
The current PE Ratio of Jazz Pharmaceuticals is 616.7. Jazz Pharmaceuticals’s PEG ratio is 0.18.
PE Ratio616.7
PS Ratio2.43
PB Ratio2.40
Price to Fair Value2.40
Price to FCF9.05
Price to Operating Cash Flow9.57
PEG Ratio0.18
Income Statement
In the last 12 months, Jazz Pharmaceuticals had revenue of 4.27B and earned -356.15M in profits. Earnings per share was -5.84.
Revenue4.27B
Gross Profit3.76B
Operating Income224.42M
Pretax Income-628.59M
Net Income-356.15M
EBITDA108.46M
Earnings Per Share (EPS)-5.84
Cash Flow
In the last 12 months, operating cash flow was 1.66B and capital expenditures -118.70M, giving a free cash flow of 1.54B billion.
Operating Cash Flow1.66B
Free Cash Flow1.54B
Free Cash Flow per Share24.55
Dividends & Yields
Jazz Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.51
52-Week Price Change122.27%
50-Day Moving Average208.26
200-Day Moving Average165.98
Relative Strength Index (RSI)53.06
Average Volume (3m)4.00
Important Dates
Jazz Pharmaceuticals upcoming earnings date is Nov 11, 2026, After Close (Confirmed).
Last Earnings DateAug 3, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date―
Financial Position
Jazz Pharmaceuticals as a current ratio of 1.86, with Debt / Equity ratio of 22.08%
Current Ratio1.86
Quick Ratio1.67
Debt to Market Cap0.52
Net Debt to EBITDA37.17
Interest Coverage Ratio1.15
Taxes
In the past 12 months, Jazz Pharmaceuticals has paid -272.44M in taxes.
Income Tax-272.44M
Effective Tax Rate0.43
Enterprise Valuation
Jazz Pharmaceuticals EV to EBITDA ratio is 132.76, with an EV/FCF ratio of 12.56.
EV to Sales3.37
EV to EBITDA132.76
EV to Free Cash Flow12.56
EV to Operating Cash Flow10.62
Balance Sheet
Jazz Pharmaceuticals has €1.62B in cash and marketable securities with €1.06B in debt, giving a net cash position of €559.80M billion.
Cash & Marketable Securities€1.62B
Total Debt€1.06B
Net Cash€559.80M
Net Cash Per Share€8.91
Tangible Book Value Per Share-€31.82
Margins
Gross margin is 60.94%, with operating margin of 5.26%, and net profit margin of -8.35%.
Gross Margin60.94%
Operating Margin5.26%
Pretax Margin-14.73%
Net Profit Margin-8.35%
EBITDA Margin2.54%
EBIT Margin-10.16%
Analyst Forecast
The average price target for Jazz Pharmaceuticals is €244.01, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€244.01
Price Target Upside8.74% Upside
Analyst ConsensusStrong Buy
Analyst Count18
Revenue Growth Forecast1.18%
EPS Growth Forecast-98.66%